Xeris Biopharma (XERS): A High-Growth Biotech Play with Strong Commercial Execution and ...

Retrieved on: 2025-08-30 14:05:31

Tags for this article:

Click the tags to see associated articles and topics

Xeris Biopharma (XERS): A High-Growth Biotech Play with Strong Commercial Execution and .... View article details on hiswai:

Excerpt

- Xeris Biopharma (XERS) reports 49% Q2 2025 revenue growth to $71.5M, driven by Recorlev and Gvoke sales. - Mixed insider transactions include 786K ...

Article found on: www.ainvest.com

View Original Article